Glycation, glycoxidation and carbonyl stress: Role in the vascular complications of Diabetes mellitus;Glicación, glicoxidación y estrés carbonílico: Relevancia en las complicaciones vasculares de la Diabetes mellitus

Revista Argentina de Endocrinologia y Metabolismo

Volumn 37, Issue 3, 2000, Pages 141-163

  McCarthy, A D ^a  

^a FACULTAD DE CIENCIAS EXACTAS   (Argentina)

Author keywords

Advanced glycation endproducts; AGE inhibitors; Diabetes Mellitus; Growth factors; Long term complications

Indexed keywords

2 ISOPROPYLIDENEHYDRAZONO 4 OXO 5 THIAZOLIDINYLACETANILIDE; ALAGEBRIUM; AMINOGUANIDINE; CARBONYL DERIVATIVE; PROTEIN INHIBITOR; PYRIDOXAMINE; UNCLASSIFIED DRUG;

ARTICLE; DIABETES MELLITUS; DRUG EFFECT; DRUG MECHANISM; DRUG RECEPTOR BINDING; ENZYME ACTIVITY; GLYCATION; OXIDATION; OXIDATIVE STRESS; PROTEIN CROSS LINKING; PROTEIN PROTEIN INTERACTION; VASCULAR DISEASE;

EID: 0034468420     PISSN: 03264610     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (124)

1. Report of the Expert Committee for the Diagnosis and Classification of Diabetes mellitus
2. Diabetes Mellitus
3. Criterios de diagnóstico y clasificación de la diabetes: Su impacto socioeconómico
4. The effect of intensive treatment of on the development and progression of long-term complications in insulin-dependent diabetes mellitus
5. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes
6. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes
7. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes
8. Efficacy of atenolol and captopril in reducing risk of microvascular and microvascular complications in type 2 diabetes
9. Recent progress in advanced glycation endproducts and diabetic complications
10. New approaches for treatment in diabetes: Aldose reductase inhibitors
11. Role of oxidative stress in development of complications in diabetes
12. Hyperglycemic pseudohypoxia and diabetic complications
13. Metabolic and vascular factors in the pathogenesis of diabetic neuropathy
14. Glycation, oxidation and lipoxidation in the development of the complications of diabetes: A carbonyl stress hypothesis
15. Role of modified lipoproteins in diabetic macroangiopathy
16. Protein kinase C activation and its role in the development of vascular complications in diabetes mellitus
17. Diabetic microvascular complications and growth factors
18. Biochemical events and cytokine interactions linking glucose metabolism to the development of diabetic nephropathy
19. Role of oxidative stress in diabetic complications: A new perspective on an old paradigm
20. Action des acides amines sur les sucres: Formation des melanoides par vole méthodique
21. Glycation of macromolecules
22. Advanced glycosylation endproducts in patients with diabetic nephropathy
23. 2-microglobulin modified with advanced glycation end products is a major component of hemodialysis-associated amyloidosis
24. RAGE and amyloid-â peptide neurotoxicity in Alzheimer's disease
25. Nonenzymatic browning in vivo: Possible process for aging of long lived proteins
26. Glicosilación no enzimática de proteínas: Su rol en las complicaciones crónicas de la diabetes y el envejecimiento
27. Glucose autoxidation and protein modification: The potential role of autoxidative glycosylation in diabetes
28. Accumulation of Maillard reaction products in skin collagen in diabetes and aging
29. Increased collagen-linked pentosidine levels and advanced glycosylation end products in early diabetic nephropathy
30. Pentosidine formation in skin correlates with severity of complications in individuals with long-standing IDDM
31. Nå-(carboxymethyl) lysine is a dominant advanced glycation end-product (AGE) antigen in tissue proteins
32. The advanced glycation end-product, Nå-(carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions
33. Modification of low-density lipoprotein contributes to the dyslipidemia of diabetes and renal insufficiency
34. Carboxymethylethanolamine: A biomarker of phospholipid modification during the Maillard reaction in vivo
35. Accelerated age-related browning of human collagen in diabetes mellitus
36. Effects of age and diabetes mellitus on the solubility and non-enzymatic glycosylation of human skin collagen
37. Abnormal lung elasticity in juvenile diabetes mellitus
38. Relation between complications of type 1 diabetes mellitus and collagen linked fluorescence
39. Formation of immunochemical advanced glycation end products precedes and correlates with early manifestations of renal and retinal disease in diabetes
40. Advanced glycosylation endproducts
41. Non-enzymatic glycosylation products on collagen covalently trap low-density lipoprotein
42. Models of the self assembly of basement membrane
43. Molecular mechanisms in basement membrane complications of diabetes: Alterations in heparin, laminin and type IV collagen association
44. The progression of renal disease
45. Studies on macro-molecular components of human glomerular basement membrane and alterations in diabetes: Decreased levels of heparan sulphate proteoglycan and laminin
46. Alterations in basement membrane (heparan sulphate) proteoglycan in diabetic mice
47. Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man
48. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells
49. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilation in experimental diabetes
50. Impaired endothelium-dependent and independent vasodilation in patients with type 2 (non-insulin-dependent) diabetes mellitus
51. Exogenous advanced glycosylation endproducts induce complex vascular dysfunction in normal animals: A model for diabetic and aging complications
52. Advanced glycosylation endproducts block the antiproliferative effect of nitric oxide
53. Non-enzymatic glycosylation of alkaline phosphatase alters its biological properties
54. Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity: A model for intracellular glycosylation in diabetes
55. Nonenzymatic glycosylation of peripheral nerve protein in diabetes mellitus
56. Nonenzymatic glycation of peripheral and central nervous system proteins in experimental diabetes mellitus
57. Recognition and uptake of human diabetic peripheral nerve myelin by macrophages
58. High-affinity-receptor-mediated uptake and degradation of glucose-modified proteins: A potential mechanism for the removal of senescent macromolecules
59. Cachectin/TNF and IL-1 induced by glucose-modified proteins: Role in normal tissue remodeling
60. Receptor-specific induction of Insulin-like growth factor-I in human monocytes by advanced glycosylation endproduct-modified proteins
61. The effect of glucose and advanced glycosylation end products on IL-6 production by human monocytes
62. Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties
63. Advanced glycation end product (AGE)-mediated induction of tissue factor in cultured endothelial cells is dependent on RAGE
64. Advanced glycation endproducts inhibit prostacyclin production and induce plasminogen activator inhibitor-1 in human microvascular endothelial cells
65. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins
66. Advanced glycation endproducts promote adhesion molecule (VCAM-1, ICAM-1) expression and atheroma formation in normal rabbits
67. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells
68. Endothelial cell dysfunction secondary to the adhesion of diabetic erythrocytes: Modulation by iloprost
69. Advanced glycation endproducts-driven angiogenesis in vitro: Induction of the growth and tube formation of human microvascular endothelial cells through autocrine vascular endothelial growth factor
70. Advanced glycation end products increase retinal vascular endothelial growth factor expression
71. Toxic action of advanced glycation end products on cultured retinal capillary pericytes and endothelial cells: Relevance to diabetic retinopathy
72. Human and rat mesangial cell receptors for glucose-modified proteins: Potential role in kidney tissue remodelling and diabetic nephropathy
73. Upregulation of mesangial growth factor and extracellular matrix synthesis by advanced glycation end products via a receptor-mediated mechanism
74. Ribozyme targeting of receptor for advanced glycation end products in mouse mesangial cells
75. Glycated tau protein in Alzheimer disease: A mechanism for induction of oxidant stress
76. Advanced glycation end products contribute to amyloidosis in Alzheimer disease
77. Receptors for advanced glycosylation endproducts in human brain: Role in brain homeostasis
78. Amyloidpeptide-receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: A proinflammatory pathway in Alzheimer disease
79. Effect of glycated collagen on proliferation of human smooth muscle cells in vitro
80. The receptor for advanced glycation end products mediates the chemotaxis of rabbit smooth muscle cells
81. 2-microglobulin modified with advanced glycation end products modulates collagen synthesis by human fibroblasts
82. Advanced glycosylation endproduct-specific receptors on human and rat T-lymphocytes mediate synthesis of interferon: Role in tissue remodeling
83. Inhibition of matrix-induced bone differentiation by advanced glycation end-products in rats
84. Diabetic and age-related enhancement of collagen-linked fluorescence in cortical bones of rats
85. Role of nonenzymatic glycosylation of type I collagen in diabetic osteopenia
86. Advanced glycation endproduct-specific receptors in rat and mouse osteoblast-like cells: Regulation with stages of differentiation
87. Effects of advanced glycation end-products on the proliferation and differentiation of osteoblast-like cells
88. Nonenzymatic glycation of type I collagen modifies interaction with UMR 201-10B preosteoblastic cells
89. Regulación del factor de crecimiento insulino-simil tipo I (IGF-I) y sus proteínas ligadoras (IGFBP) por productos de glicación avanzados (PGA): Rol en el desarrollo osteoblástico
90. Advanced glycation endproducts stimulate interleukin-6 production by human bone-derived cells
91. Advanced glycation end products enhance osteoclast induced bone resorption in cultured mouse unfractionated bone cells and in rats implanted subcutaneously with devitalised bone particles
92. Cloning and expression of a cell-surface receptor for advanced glycosylation endproducts of proteins
93. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy: Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats
94. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for AGE (sRAGE)
95. Blockade of RAGE suppresses periodontitis-associated bone loss in diabetic mice
96. The endothelial cell binding site for advanced glycation endproducts consists of a complex: An integral membrane protein and a lactoferrin-like polypeptide
97. Activation of the receptor for advanced glycation end products triggers a p21ras-dependent mitogen-activated protein kinase pathway regulated by oxidant stress
98. A redox-triggered ras-effector interaction
99. Localization of the human gene for advanced glycosylation-specific receptor (AGER) to chromosome 6p 213
100. Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products
101. Two novel rat liver membrane proteins that bind advanced glycosylation endproducts: Relationship to macrophage receptor for glucose-modified proteins
102. Molecular identity and cellular distribution of advanced glycation endproduct receptors: Relationship of p60 to OST-48 and p90 to 80K-H membrane proteins
103. DAD1, the defender against apoptotic cell death, is a subunit of the mammalian oligosaccharyltransferase
104. Purification of two distinct proteins of approximate Mr 80,000 from human epithelial cells and identification as proper substrates for protein kinase C
105. Signal transduction pathway of human fibroblast growth factor receptor 3
106. Cell activation by glycated proteins: AGE receptors, receptor recognition factors and functional classification of AGEs
107. Identification of galectin-3 as a high-affinity binding protein for advanced glycation end products (AGE): A new member of the AGE-receptor complex
108. The major non-integrin laminin binding protein of macrophages is identical to carbohydrate binding protein 35 (Mac-2)
109. Expression and function of galectin-3, a beta-galactoside binding lectin, in human monocytes and macrophages
110. Galectin-3 expression in human atherosclerotic lesions
111. The diabetic milieu modulates the advanced glycation end product-receptor complex in the mesangium by inducing or upregulating galectin-3 expression
112. Molecular flypaper, host defense and atherosclerosis - Structure, binding-properties and functions of macrophage scavenger receptors
113. Microglial cells internalize aggregates of the Alzheimer's disease amyloid beta-protein via a scavenger receptor
114. Uptake of proteins modified with 3-deoxyglucosone, a Maillard reaction intermediate, by the type I macrophage scavenger receptor
115. Macrophage scavenger receptor mediates the endocytic uptake and degradation of advanced glycation endproducts of the Maillard reaction
116. Advanced glycation end products are eliminated by scavenger-receptor-mediated endocytosis in hepatic sinusoidal Kupffer and endothelial cells
117. Macrophages adhere to glucose-modified basement membrane collagen IV via their scavenger receptors
118. Aminoguanidine prevents diabetes-induced arterial wall cross-linking
119. Mechanistic studies of advanced glycosylation endproduct inhibition by aminoguanidine
120. In vitro kinetic studies of formation of antigenic advanced glycation endproducts (AGEs): Novel inhibition of post-Amadori glycation pathways
121. Progression of nephropathy in spontaneously diabetic rats is prevented by OBP-9195, a novel inhibitor of advanced glycation
122. An agent cleaving glucose-derived protein crosslinks in vitro and in vivo
123. Breakers of advanced glycation end products restore large artery properties in experimental diabetes
124. Advanced glycosylation end products in diabetic complications: Biochemical basis and prospects for therapeutic intervention